Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate
Antibody Therapeutics · 28.03.2025 · 8 (2) · 145-156
DOI: 10.1093/abt/tbaf006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 10.04.2025. Verfasst von Hwai Wen Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research & Development, BioAtla Inc., San Diego, CA 92121, United States. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BioAtla Inc.
Abstract (Originalsprache)
Background
AXL, a tyrosine kinase receptor, is over-expressed in many solid and hematologic cancers, promoting progression and poor clinical outcomes. It also contributes to resistance against chemotherapeutic agents, especially tyrosine kinase inhibitors, by upregulating AXL signaling or switching oncogenic pathways. These factors make AXL an attractive therapeutic target. However, early attempts with naked antibody therapies failed due to the high doses need for efficacy, and antibody-drug conjugates (ADCs) targeting AXL were hindered by off-tumor toxicities due to its expression on normal tissues.
Methods
To address these issues, we developed a novel, conditionally active biologic ADC, mecbotamab vedotin (BA3011), which selectively binds to AXL in the acidic tumor microenvironment. In healthy tissue, binding to AXL is substantially diminished due to a powerful selection mechanism utilizing naturally occurring, physiological chemicals referred to as Protein-associated Chemical Switches. BA3011 was tested in vitro and in vivo against AXL expressing cancer cells.
Results
Mecbotamab vedotin demonstrates the expected AXL, tumor-specific binding properties and effectively induced lysis of AXL-positive cancer cell lines in vitro. In vivo, mecbotamab vedotin exhibited potent and lasting antitumor effects in human cancer xenograft mouse models. Furthermore, in nonhuman primates, mecbotamab vedotin demonstrated excellent tolerability at doses of up to 5 mg/kg and maintained linker-payload stability in vivo.
Conclusions
These findings indicate that mecbotamab vedotin has the potential to be a robust and less toxic therapeutic agent, offering promise as a treatment for patients with AXL-positive cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research & Development, BioAtla Inc., San Diego, CA 92121, United States.
Förderung
- BioAtla Inc
Zitieren
APA
Chang, H. W., Wang, J., Liu, H., Xing, C., Chen, J., Frey, G., Boyle, W. J., & Short, J. M. (2025). Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate. Antibody Therapeutics, 8(2), 145-156. https://doi.org/10.1093/abt/tbaf006
Vancouver
Chang HW, Wang J, Liu H, Xing C, Chen J, Frey G, et al. Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate. Antibody Therapeutics. 2025;8(2):145-156. doi:10.1093/abt/tbaf006
BibTeX
@article{Chang2025,
author = {Chang, Hwai Wen and Wang, Jing and Liu, Haizhen and Xing, Charles and Chen, Jian and Frey, Gerhard and Boyle, William J and Short, Jay M},
title = {Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate},
journal = {Antibody Therapeutics},
year = {2025},
volume = {8},
number = {2},
pages = {145--156},
doi = {10.1093/abt/tbaf006}
}
EUVIMED